1236. Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Healthy Infants in the United States

BACKGROUND: A 20-valent pneumococcal conjugate vaccine (PCV20) is being developed to extend protection against pneumococcal disease beyond that of the 13-valent pneumococcal vaccine (PCV13). This is the first safety and immunogenicity study of PCV20 in healthy infants. METHODS: This randomized, doub...

Descripción completa

Detalles Bibliográficos
Autores principales: Senders, Shelly, Klein, Nicola P, Lamberth, Erik, Thompson, Allison, Drozd, Jelena, Trammel, James, Peng, Yahong, Giardina, Peter, Jansen, Kathrin U, Gruber, William C, Scott, Daniel, Watson, Wendy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777493/
http://dx.doi.org/10.1093/ofid/ofaa439.1421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777493/
http://dx.doi.org/10.1093/ofid/ofaa439.1421

Ejemplares similares